Please assess the completion status of the following clinical trial:

Trial Title: Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical Practice

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent prior to any study related procedures.~* Subjects male or female, aged 18 years or older.~* Upper limb spasticity post stroke or traumatic brain injury.~* Spasticity position pattern type 1, 3 or 4.~* Elbow flexor muscles spasticity MAS 2 to 3.~* At least 2 consecutive previous treatment cycles of BoNT-A for current diagnosis.~* The latest treatment cycle demonstrating good treatment efficacy where the Dysport dose administered was considered to be adequate according to Investigator judgement.~* Need of the same treatment modality in muscle (m.) brachialis, m. biceps brachii, m. brachioradialis, m. flexor carpi ulnaris, m. flexor carpi radialis as the previous treatment cycle.~* Last BoNT-A treatment 12-24 weeks ago.~Exclusion Criteria:~* Poor response to BoNT-A treatment, according to Investigator.~* Need of Dysport doses \>800 U in the upper limb.~* Concomitant treatment with BoNT-A for other indications than spasticity.~* Any elbow flexor contracture prohibiting MAS evaluation and/or elbow flexion improvement of at least 1 step on the MAS.~* Cutaneous or joint inflammation in the affected upper limb.~* Was likely to start other spasticity treatment during the study.~* Was likely to start physiotherapy treatment during the study.~* Other ongoing neurological disorder (e.g., myasthenia gravis).~* History of dysphagia or aspiration.~* Use of agents interfering with neuromuscular transmission (e.g., aminoglycosides).~* Treated with an investigational medicinal product within 30 days before start of the study.~* Known sensitivity to BoNT-A or any components of Dysport.~* Was at risk of pregnancy or was lactating. Females of childbearing potential must have provided a negative pregnancy test (urinary human chorionic gonadotropin (U-hCG)) at Visit 1 and must have been using adequate contraception. Non-childbearing potential was defined as post-menopause for at least one year, surgical sterilisation or hysterectomy at least three months before the start of the study.~* Had a history of, or known current, problems with alcohol or drug abuse.~* Had a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.~* Had abnormal Baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might have jeopardised the subject's safety or decreased the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NMJ Targeted (Type: EXPERIMENTAL): NMJ targeted technique and low-concentration dilution (Dysport 100 U/mL). The same number and sites of injections/deposits per muscle were given as per prestudy. With a Dysport dilution of 300 U/mL the volume to be injected varied between 0.1 mL and 0.7 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment.
- Current Clinical Practice (Type: ACTIVE_COMPARATOR): Current clinical practice technique and high-concentration dilution (Dysport 300 U/mL).~A single injection per muscle was given in the midline of the band of NMJ zones. With a Dysport dilution of 100 U/mL the volume to be injected varied between 0.4 mL and 2.0 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).